Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know
Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.
![Pfizer logo seen on Pfizer World Headquarters in New York City](https://cdn.mos.cms.futurecdn.net/GYVrfyEscF5rsJnNFidSLo-415-80.jpg)
Pfizer (PFE) stock is trading in negative territory Tuesday even after the pharmaceutical giant topped analysts' expectations for its second quarter and raised its full-year outlook.
In the three months ended June 30, Pfizer said its revenue increased 2.1% year-over-year to $13.3 billion, thanks in part to 22% revenue growth in the U.S. to $7.9 billion. Its earnings per share (EPS) declined 10.4% from the year-ago period to 60 cents.
"This was Pfizer's first quarter of topline revenue growth, on a year-over-year basis, since the fourth quarter of 2022 when our COVID revenues peaked," said Pfizer Chief Financial Officer David Denton in a statement. "Importantly, the strong 14% operational revenue growth of our non-COVID products in the second quarter demonstrates our continued focus on commercial execution."
![https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png](https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png)
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The results topped analysts' expectations. Wall Street was anticipating revenue of $13 billion and earnings of 46 cents per share, according to Yahoo Finance.
"Pfizer once again delivered better-than-expected results at both the top and bottom line, wrote Lee Brown, global sector lead for healthcare at Third Bridge, in an emailed statement.
In addition to solid sales of Pfizer's heart disease drugs Vyndaqel and Vyndamax and its blood-clot treatment Eliquis, Brown highlighted Pfizer's cost-saving initiatives, "which are on track to deliver at least $4 billion in net cost savings by the end of this year, as well as recently launched manufacturing optimization program that is targeting cost savings of roughly $1.5 billion by the end of 2027."
Pfizer updates its full-year outlook
"With a successful first half now completed, we believe it is appropriate to update our full year earnings outlook to reflect our strong business performance," Denton said in prepared remarks.
Pfizer now anticipates revenue in the range of $59.5 billion to $62.5 billion and EPS in the range of $2.45 to $2.65 in 2024. This is up from its previous forecast of revenue in the range of $58.5 billion to $61.5 billion and earnings per share in the range of $2.15 to $2.35.
"We are clearly striving to bring about improved performance on both the top-and-bottom lines through focus, execution and delivering on our near-term commercial and financial goals," Denton said. "2024 is clearly a foundation year for Pfizer."
Is PFE stock a buy, sell or hold?
Not only is Pfizer one of Kiplinger's best stocks to buy, but Wall Street is also bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for PFE stock is $32.19, representing an upside of more than 7% to current levels. Additionally, the consensus recommendation is Buy.
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
5 Stocks to Buy for a Trump Presidency
The race for the White House is heating up and these five stocks are set to benefit if Donald Trump claims victory.
By Will Ashworth Published
-
6 Target-Date Funds to Buy For Your Retirement
These six target-date funds are good set-it-and-forget-it options that are a staple of retirement plans.
By Nellie S. Huang Published
-
5 Stocks to Buy for a Trump Presidency
The race for the White House is heating up and these five stocks are set to benefit if Donald Trump claims victory.
By Will Ashworth Published
-
Six Target-Date Funds to Buy For Your Retirement
These six target-date funds are good set-it-and-forget-it options that are a staple of retirement plans.
By Nellie S. Huang Published
-
How to Deal With Inflation: Advice From a Financial Adviser
Higher prices are hitting everyone, but if you're especially hurting, here are some ways that could help you to cope.
By Kelsey M. Simasko, Esq. Published
-
Stock Market Today: Dow Dives 410 Points After August Jobs Miss
A big slump in tech stocks thanks to Broadcom's post-earnings slide put pressure on the main indexes too.
By Karee Venema Published
-
Mixed Jobs Report Keeps Fed on Track for Rate Cuts: What the Experts Are Saying
Jobs Report The Fed will cut rates this month. The only question is by how much.
By Dan Burrows Published
-
Apple Stock's a Buy Ahead of Apple Event 2024
Apple stock is on Wall Street's radar ahead of the tech giant's annual September product event, which begins on Monday. Here's what analysts are saying and what you can expect to see.
By Joey Solitro Published
-
UiPath Stock's Price Struggles Continue After Earnings: What to Know
UiPath stock has been a market laggard this year and losses are accelerating even after the company's beat-and-raise quarter.
By Joey Solitro Published
-
Why Broadcom Stock Is Still a Buy After Earnings
Broadcom stock is sinking Friday after the chipmaker's outlook fell short, but Wall Street remains bullish. Here's what they're saying.
By Joey Solitro Published